24930 Federal Register / Vol. 80, No. 84 / Friday, May 1, 2015 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket Number CDC–2015–0020; NIOSH 

156–A] 

Request for the Technical Review of 14 

Draft Immediately Dangerous to Life or 

Health (IDLH) Value Profiles 

AGENCY: National Institute for 

Occupational Safety and Health 

(NIOSH) of the Centers for Disease 

Control and Prevention (CDC), 

Department of Health and Human 

Services (HHS). 

ACTION: Request for information and 

comment. 

SUMMARY: The National Institute for 

Occupational Safety and Health 

(NIOSH) of the Centers for Disease 

Control and Prevention (CDC) is 

conducting a public review of the draft 

immediately dangerous to life or health 

(IDLH) values and support technical 

documents, entitled IDLH Values 

Profiles, for 14 chemicals. NIOSH is 

requesting technical reviews of the draft 

IDLH Value Profiles. 

DATES: Electronic or written comments 

on the 14 documents contained within 

Group A must be received on or before 

June 30, 2015. 

ADDRESSES: You may submit comments, 

identified by CDC–2015–0020 and 

docket number NIOSH 156–A, by either 

of the two following methods: 

• Federal eRulemaking Portal: http:// 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: National Institute for 

Occupational Safety and Health, NIOSH 

Docket Office, 1090 Tusculum Avenue, 

MS C–34, Cincinnati, OH 45226. 

Instructions: All information received 

in response to this notice must include 

the agency name and docket number 

[CDC–2015–0020; NIOSH 156–A]. All 

relevant comments received will be 

posted without change to 

www.regulations.gov, including any 

personal information provided. All 

electronic comments should be 

formatted as Microsoft Word. For access 

to the docket to read background 

documents or comments received, go to 

www.regulations.gov. All information 

received in response to this notice will 

also be available for public examination 

and copying at the NIOSH Docket 

Office, 1150 Tusculum Avenue, Room 

155, Cincinnati, OH 45226. 

FOR FURTHER INFORMATION CONTACT: G. 

Scott Dotson, NIOSH, Robert A. Taft 

Laboratories, MS C–32, 1090 Tusculum 

Avenue, Cincinnati, OH 45226. (513) 

533–8540 (not a toll free number). 

SUPPLEMENTARY INFORMATION: The draft 

documents are based on the process 

outlined in the NIOSH Current 

Intelligence Bulletin 66—Derivation of 

Immediately Dangerous to Life or Health 

(IDLH) Values http://www.cdc.gov/ 

niosh/docs/2014-100/pdfs/2014- 

100.pdf. To facilitate the review of these 

documents, NIOSH requests that the 

following questions be taken into 

consideration: 

1. Does this document clearly outline 

the health hazards associated with acute 

(or short-term) exposures to the 

chemical? If not, what specific 

information is missing from the 

document? 

2. Are the rationale and logic behind 

the derivation of an IDLH value for a 

specific chemical clearly explained? If 

not, what specific information is needed 

to clarify the basis of the IDLH value? 

3. Are the conclusions supported by 

the data? 

4. Are the tables clear and 

appropriate? 

5. Is the document organized 

appropriately? If not, what 

improvements are needed? 

6. Are you aware of any scientific data 

reported in governmental publications, 

databases, peer-reviewed journals, or 

other sources that should be included 

within this document? 

NIOSH seeks comments on 14 draft 

IDLH values and IDLH Value Profiles. 

The draft IDLH Value Profiles were 

developed to provide the scientific 

rationale behind derivation of IDLH 

values for the following chemicals: 

Document No. Chemical(s) 

A–01 ........................... Acrylonitrile ...................................................................................................................................... (CAS# 107–13–1) 

A–02 ........................... Benzonitrile ...................................................................................................................................... (CAS# 100–47–0) 

A–03 ........................... Methyl isocyanate ........................................................................................................................... (CAS# 624–83–9) 

A–04 ........................... HCFC–141B .................................................................................................................................... (CAS# 1717–00–6) 

A–05 ........................... Chloroacetyl chloride ....................................................................................................................... (CAS# 79–04–9) 

A–06 ........................... Chlorine pentafluoride ..................................................................................................................... (CAS# 13637–63–3) 

Bromine pentafluoride ..................................................................................................................... (CAS# 7789–30–2) 

A–07 ........................... Iron pentacarbonyl .......................................................................................................................... (CAS# 13463–40–6) 

A–08 ........................... 1,3-Butadiene .................................................................................................................................. (CAS# 106–99–0) 

A–09 ........................... Diketene .......................................................................................................................................... (CAS# 674–82–8) 

A–10 ........................... Furan ............................................................................................................................................... (CAS# 110–00–9) 

A–11 ........................... Hexafluoroacetone .......................................................................................................................... (CAS# 684–16–2) 

A–12 ........................... n-Butyl acrylate ............................................................................................................................... (CAS# 141–32–2) 

A–13 ........................... Peracetic acid .................................................................................................................................. (CAS# 79–21–0) 

A–14 ........................... Butane ............................................................................................................................................. (CAS# 106–97–8). 

Each IDLH Value Profile provides a 

detailed summary of the health hazards 

of acute exposures to high airborne 

concentrations and the rationale for the 

proposed IDLH value with the 

chemical(s) of interest. 

In 2013, NIOSH published Current 

Intelligence Bulletin (CIB) 66— 

Derivation of Immediately Dangerous to 

Life or Health (IDLH) Values [NIOSH 

2014–100; http://www.cdc.gov/niosh/ 

docs/2014-100/pdfs/2014-100.pdf]. The 

draft documents available for public 

review use the methodology in this 

document. Since the establishment of 

the IDLH values in the 1970s, NIOSH 

has continued to review available 

scientific data to improve the protocol 

used to derive acute exposure 

guidelines, in addition to the chemicalspecific IDLH values. The information 

presented in this CIB represents the 

most recent update of the scientific 

rationale and the methodology (hereby 

referred to as the IDLH methodology) 

used to derive IDLH values. The 

primary objectives of this document are 

to: 

1. Provide a brief history of the 

development of IDLH values 

2. Update the scientific basis and risk 

assessment methodology used to derive 

IDLH values from quality data 

3. Provide transparency behind the 

rationale and derivation process for 

IDLH values 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 80, No. 84 / Friday, May 1, 2015 / Notices 24931 

4. Demonstrate how scientifically 

credible IDLH values can be derived 

from available data resources 

The IDLH methodology outlined in 

this CIB reflects the modern principles 

and understanding in the fields of risk 

assessment, toxicology, and 

occupational health and provides the 

scientific rationale for the derivation of 

IDLH values based on contemporary risk 

assessment practices. According to this 

protocol, IDLH values are based on 

health effects considerations determined 

through a critical assessment of the 

toxicology and human health effects 

data. This approach ensures that the 

IDLH values reflect an airborne 

concentration of a substance that 

represents a high-risk situation that may 

endanger workers’ lives or health. 

Relevant airborne concentrations are 

typically addressed through the 

characterization of inhalation 

exposures; however, airborne chemicals 

can also contribute to toxicity through 

other exposure routes, such as the skin 

and eyes. In this document, airborne 

concentrations are referred to as acute 

inhalation limits or guidelines to adhere 

to commonly used nomenclature. 

The emphasis on health effects is 

consistent with both the traditional use 

of IDLH values as a component of the 

respirator selection logic and the 

growing applications of IDLH values in 

Risk Management Plan (RMPs) for nonroutine work practices governing 

operations in high-risk environments 

(e.g., confined spaces) and the 

development of Emergency 

Preparedness Plans (EPPs). Incorporated 

in the IDLH methodology are the 

standing guidelines and procedures 

used for the development of 

community-based acute exposure limits 

called Acute Exposure Guideline Levels 

(AEGLs). The inclusion of the AEGL 

methodology has helped ensure that the 

health-based IDLH values derived with 

use of the guidance provided in this 

document are based on validated 

scientific rationale. 

The IDLH methodology is based on a 

weight-of-evidence approach that 

applies scientific judgment for critical 

evaluation of the quality and 

consistency of scientific data and in 

extrapolation from the available data to 

the IDLH value. The weight-of-evidence 

approach refers to critical examination 

of all available data from diverse lines 

of evidence and the derivation of a 

scientific interpretation on the basis of 

the collective body of data, including its 

relevance, quality, and reported results. 

This is in contrast to a purely 

hierarchical or strength-of-evidence 

approach, which relies on rigid decision 

criteria for selecting a critical adverse 

effect, a point of departure (POD), or the 

point on the dose–response curve from 

which dose extrapolation is initiated 

and for applying default uncertainty 

factors (UFs) to derive the IDLH value. 

Conceptually, the derivation process for 

IDLH values is similar to that used in 

other risk assessment applications, 

including these steps: 

1. Hazard characterization. 

2. Identification of critical adverse 

effects. 

3. Identification of a POD. 

4. Application of appropriate UFs, 

based on the study and POD. 

Dated: April 24, 2015. 

John Howard, 

Director, National Institute for Occupational 

Safety and Health, Centers for Disease Control 

and Prevention. 

[FR Doc. 2015–10295 Filed 4–30–15; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–15–15IG] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

The Centers for Disease Control and 

Prevention (CDC) has submitted the 

following information collection request 

to the Office of Management and Budget 

(OMB) for review and approval in 

accordance with the Paperwork 

Reduction Act of 1995. The notice for 

the proposed information collection is 

published to obtain comments from the 

public and affected agencies. 

Written comments and suggestions 

from the public and affected agencies 

concerning the proposed collection of 

information are encouraged. Your 

comments should address any of the 

following: (a) Evaluate whether the 

proposed collection of information is 

necessary for the proper performance of 

the functions of the agency, including 

whether the information will have 

practical utility; (b) Evaluate the 

accuracy of the agencies estimate of the 

burden of the proposed collection of 

information, including the validity of 

the methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; (d) Minimize the burden of 

the collection of information on those 

who are to respond, including through 

the use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and (e) Assess information 

collection costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570 or 

send an email to omb@cdc.gov. Written 

comments and/or suggestions regarding 

the items contained in this notice 

should be directed to the Attention: 

CDC Desk Officer, Office of Management 

and Budget, Washington, DC 20503 or 

by fax to (202) 395–5806. Written 

comments should be received within 30 

days of this notice. 

Proposed Project 

Public Health Associate Program 

(PHAP) Alumni Assessment—New— 

Office for State, Tribal, Local, and 

Territorial Support (OSTLTS)— 

(proposed), Centers for Disease Control 

and Prevention (CDC). 

Background and Brief Description 

The Centers for Disease Control and 

Prevention (CDC) works to protect 

America from health, safety and security 

threats, both foreign and in the U.S. 

CDC strives to fulfill this mission, in 

part, through a competent and capable 

public health workforce. One 

mechanism to developing the public 

health workforce is through training 

programs like the Public Health 

Associate Program (PHAP). 

The mission of PHAP is to train and 

provide experiential learning to early 

career professionals who contribute to 

the public health workforce. PHAP 

targets recent graduates with bachelors 

or masters degrees who are beginning a 

career in public health. Each year, a new 

cohort of up to 200 associates is 

enrolled in the program. Associates are 

CDC employees who complete two-year 

assignments in a host site (i.e., a state, 

tribal, local, or territorial health 

department or non-profit organization). 

Host sites design their associates’ 

assignments to meet their agency’s 

unique needs while also providing onthe-job experience that prepares 

associates for future careers in public 

health. Associates also receive CDCbased training in core public health 

concepts and topics to provide the 

knowledge, skills, and abilities 

necessary to succeed in their 

assignments and provide a foundation 

for a career in public health. PHAP 

hosts an initial in-person orientation 

and annual public health training at 

CDC and offers long-distance learning 

opportunities throughout the program. It 

is the goal of PHAP that following 

participation in the two-year program, 

alumni will seek employment within 

the public health system (i.e., federal, 

mstockstill on DSK4VPTVN1PROD with NOTICES